These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34707005)

  • 61. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
    Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer.
    Wu L; Chen M; Lin Y; Zeng B; Guo W; Chen L; Li Y; Yu L; Li J; Chen X; Zhang W; Li S; Cai W; Zhang K; Jin X; Huang J; Lin Q; Yang Y; Fu F; Wang C
    Am J Surg Pathol; 2024 Jan; 48(1):27-35. PubMed ID: 38117286
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
    Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of response to neoadjuvant chemotherapy on surgical modality in patients with T1-2N0-1M0 triple-negative breast cancer.
    Chang L; Liu D; Hao Q; Ren X; Liu P; Liu X; Wei Y; Lin S; Ma X; Wu H; Kang H; Wang M
    J Cancer Res Clin Oncol; 2024 Aug; 150(8):378. PubMed ID: 39085623
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Platinum-based chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Extent of surgical procedure in triple negative breast carcinomas.
    Kotal J; Petrů V; Kosáč P; Vážan P; Zábojníková M; Jančík P; Ratajský M; Lajmar K; Dudešek B; Duben J; Holík P; Gatěk J
    Rozhl Chir; 2023; 102(4):159-164. PubMed ID: 37344196
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic Roles of Neutrophil-to-Lymphocyte Ratio and Stromal Tumor-Infiltrating Lymphocytes and Their Relationship in Locally Advanced Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
    Dong X; Liu C; Yuan J; Wang S; Ding N; Li Y; Wu Y; Xiao Z
    Breast Care (Basel); 2021 Aug; 16(4):328-334. PubMed ID: 34602938
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study.
    Peng J; Hong Y; Chen Q; Xu F; Zhang D; Yao J; Zou Q; Yuan L; Li L; Long Q; Liao L; Liu M; Liu X; Wang S; Yi W
    Front Endocrinol (Lausanne); 2024; 15():1347762. PubMed ID: 38567311
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
    Bagegni NA; Tao Y; Ademuyiwa FO
    PLoS One; 2019; 14(9):e0222358. PubMed ID: 31536530
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adjuvant Capecitabine after Neoadjuvant Chemotherapy in Triple Negative Breast Cancer with Lymph Node Metastasis.
    Oner I; Turkel A; Karacin C; Seyran E; Tolunay Br PK; Cakmak Oksuzoglu OB
    J Coll Physicians Surg Pak; 2023 Sep; 33(9):1012-1018. PubMed ID: 37691363
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy.
    Goto W; Kashiwagi S; Takada K; Asano Y; Ogisawa K; Morisaki T; Shibutani M; Tanaka H; Maeda K
    Eur J Med Res; 2023 Jan; 28(1):2. PubMed ID: 36593486
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
    Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
    Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.
    Chen JH; Addanki S; Roy D; Bassett R; Kalashnikova E; Spickard E; Kuerer HM; Meas S; Sarli VN; Korkut A; White JB; Rauch GM; Tripathy D; Arun BK; Barcenas CH; Yam C; Sethi H; Rodriguez AA; Liu MC; Moulder SL; Lucci A
    BMC Cancer; 2024 Aug; 24(1):1016. PubMed ID: 39148033
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
    Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
    Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Efficacy and survival outcomes of dose-dense carboplatin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer].
    Liu Y; Xiu M; Wang X; Li Q; Wang JY; Fan Y; Li Q; Chen SS; Cai RG; Mo HN; Ma F; Luo Y; Xu BH; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):178-184. PubMed ID: 35184463
    [No Abstract]   [Full Text] [Related]  

  • 76. Strong impact of pathological node-negative on long-term overall survival of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy.
    Nogi H; Kamio M; Toriumi Y; Nagasaki E; Suzuki M; Takeyama H
    Mol Clin Oncol; 2021 May; 14(5):99. PubMed ID: 33815791
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
    Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Herrero-Vicent C; Guerrero A; Gavilá J; Gozalbo F; Hernández A; Sandiego S; Algarra MA; Calatrava A; Guillem-Porta V; Ruiz-Simón A
    Ecancermedicalscience; 2017; 11():759. PubMed ID: 28900472
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
    Yagata H; Kajiura Y; Yamauchi H
    Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).
    Shim SJ; Park W; Huh SJ; Choi DH; Shin KH; Lee NK; Suh CO; Keum KC; Kim YB; Ahn SD; Kim SS; Ha SW; Chie EK; Kim K; Shin HS; Kim JH; Lee HS
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):65-72. PubMed ID: 24161425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.